Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.43 |
| ▸ | LIPC | P11150 | 4/20 | 0.43 |
| ▸ | LPL | P06858 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1409542 | 0.80 | LIPG (0.47) | LIPGLIPCLPLHSD11B1ALDH1A1 | |
| SCHEMBL1410120 | 0.77 | LIPG (0.44) | LIPGLIPCLPLFFAR4 | |
| SCHEMBL12210016 | 0.70 | LIPG (0.47) | LIPGLIPCLPLFFAR4 | |
| SCHEMBL12210096 | 0.70 | LIPG (0.61) | LIPGLIPCLPLFFAR4 | |
| SCHEMBL1410343 | 0.70 | LMNA (0.55) | LIPGLPLHSD11B1ALDH1A1LMNA | |
| SCHEMBL1410556 | 0.70 | LIPG (0.60) | LIPGLIPCLPLFFAR4 | |
| SCHEMBL1410458 | 0.70 | LIPG (0.46) | LIPGLIPCLPLFFAR4 | |
| SCHEMBL13580724 | 0.69 | LIPG (0.44) | LIPGLIPCLPLALDH1A1LMNA | |
| SCHEMBL1410377 | 0.68 | NOTUM (0.44) | ACACBFFAR4 | |
| SCHEMBL15642892 | 0.68 | LIPG (0.42) | LIPGLIPCLPLALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | LIPG 3938/4885LIPC 1690/4885LPL 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.